UConn Health announced a second collaboration with Alexion Pharmaceuticals, Inc., headquartered in New Haven, CT, in an effort to seek out new and novel therapeutic interventions for treating rare and debilitating diseases.

Alexion previously collaborated with Dr. David Goldhamer from UConn’s Stem Cell Institute and the Department of Molecular and Cell Biology to further understand the pathophysiology of certain disorders and to test potential therapeutics using relevant disease models developed by Dr. Goldhamer.